BR112020000207A2 - composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida - Google Patents

composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida Download PDF

Info

Publication number
BR112020000207A2
BR112020000207A2 BR112020000207-0A BR112020000207A BR112020000207A2 BR 112020000207 A2 BR112020000207 A2 BR 112020000207A2 BR 112020000207 A BR112020000207 A BR 112020000207A BR 112020000207 A2 BR112020000207 A2 BR 112020000207A2
Authority
BR
Brazil
Prior art keywords
enzalutamide
dosage form
oral
pharmaceutical composition
weight
Prior art date
Application number
BR112020000207-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Shah Dharmesh Mahendrabhai
Badiger Aravind Manappa
Choksi Rakshit Ketanbhai
Patel Bhavesh Naginbhai
Salunkhe Piyusha Sharad
Soni Niraj Ramnivedan
Original Assignee
Bdr Pharmaceuticals International Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64950639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020000207(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bdr Pharmaceuticals International Private Limited filed Critical Bdr Pharmaceuticals International Private Limited
Publication of BR112020000207A2 publication Critical patent/BR112020000207A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020000207-0A 2017-07-04 2017-11-21 composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida BR112020000207A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721023465 2017-07-04
IN201721023465 2017-07-04
PCT/IB2017/057273 WO2019008426A1 (fr) 2017-07-04 2017-11-21 Nouvelle composition de forme galénique orale d'enzalutamide et procédé de fabrication de celle-ci

Publications (1)

Publication Number Publication Date
BR112020000207A2 true BR112020000207A2 (pt) 2020-07-07

Family

ID=64950639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020000207-0A BR112020000207A2 (pt) 2017-07-04 2017-11-21 composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida

Country Status (7)

Country Link
BR (1) BR112020000207A2 (fr)
CL (1) CL2020000017A1 (fr)
MX (1) MX2020000213A (fr)
PH (1) PH12020500045A1 (fr)
RU (1) RU2020105102A (fr)
WO (1) WO2019008426A1 (fr)
ZA (1) ZA202000609B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200015830A (ko) * 2014-02-05 2020-02-12 레크 파마슈티칼스 디.디. 안드로겐 수용체 길항제의 고체 제약 조성물

Also Published As

Publication number Publication date
MX2020000213A (es) 2020-08-17
ZA202000609B (en) 2021-08-25
RU2020105102A (ru) 2021-08-04
PH12020500045A1 (en) 2020-11-09
CL2020000017A1 (es) 2020-05-22
WO2019008426A1 (fr) 2019-01-10

Similar Documents

Publication Publication Date Title
ES2855426T3 (es) Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen
ES2271924T3 (es) Composicion farmaceutica que contiene fenofibrato y procedimiento de preparacion.
ES2957912T3 (es) Composiciones farmacéuticas que comprenden nilotinib
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
KR101072909B1 (ko) 경구고형의약
BRPI0721651B1 (pt) comprimido farmacêutico e usos deste na fabricação de um medicamento para tratamento de trombocitopenia e para agonizar o receptor tpo
BRPI0212922B1 (pt) Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição
PL200957B1 (pl) Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
JP2014012725A (ja) 使用
PT85353B (pt) Processo de preparacao de composicoes farmaceuticas de libertacao controlada e de matriz a base de alcool alifatico e resina acrilica
WO2014190898A1 (fr) Préparation d'isothiocyanates
PT2018158E (pt) Nova forma de administração de racecadotril
EA035686B1 (ru) Препараты, содержащие 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол
CN110292575B (zh) 药物组合物
JP2022162149A (ja) タクロリムスを含む徐放性薬剤学的製剤
EP1154762A1 (fr) Compositions de capsules pharmaceutiques contenant de la loratadine et de la pseudoephedrine
BR112020000207A2 (pt) composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida
WO2011113320A1 (fr) Compositions pharmaceutiques comprenant de la dronédarone
JP2814513B2 (ja) 溶出性の改良された製剤組成物
KR20090086686A (ko) 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법
KR102486126B1 (ko) 알펠리십을 포함하는 제약 조성물
CA3190856A1 (fr) Formes posologiques solides de palbociclib
ES2665868T3 (es) Comprimido que contiene material compuesto con ciclodextrina
CA2520813C (fr) Formulations de derives d'alkylene dioxybenzene a liberation prolongee servant d'antagonistes du recepteur 5-ht1a
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, E PORTARIA INPI NO 334 DE 24/09/2020, QUANTO AOS PRAZOS VENCIDOS ENTRE 16/09/2020 A 25/09/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]